Mark Verratti
Vermögen: 4 Mio $ am 30.06.2026
Vermögen: 4 Mio $ am 30.06.2026
Mark Steven Verratti is currently Managing Director at Myriad Genetics GmbH and Chief Operating Officer at Myriad Genetics, Inc. Former positions include Vice President-Sales at LivaNova USA, Inc. from 2005 to 2012, and SVP, Chief Sales & Business Development Officer at Assurex Health, Inc. Education includes undergraduate studies at The Pennsylvania State University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 14.04.2026 | 629’646 ( 0.67% ) | 4 Mio $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MYRIAD GENETICS, INC. | Geschäftsführer | 30.04.2025 |
Myriad Genetics GmbH
Myriad Genetics GmbH Pharmaceuticals: MajorHealth Technology Develops therapeutic and predictive medicine products | Vorstandsvorsitzender | - |
| Unternehmen | Position | Ende |
|---|---|---|
Assurex Health, Inc.
Assurex Health, Inc. Pharmaceuticals: MajorHealth Technology Operates as a personalized medicine company | Präsident | - |
| CYBERONICS, INC. | Vertrieb & Marketing | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
LivaNova USA, Inc.
LivaNova USA, Inc. Medical SpecialtiesHealth Technology Engages in design, development, sale and marketing of implantable medical devices | Health Technology |
Myriad Genetics, Inc.
Myriad Genetics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic and predictive medicine products | Health Technology |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Assurex Health, Inc.
Assurex Health, Inc. Pharmaceuticals: MajorHealth Technology Operates as a personalized medicine company | Health Technology |
Myriad Genetics GmbH
Myriad Genetics GmbH Pharmaceuticals: MajorHealth Technology Develops therapeutic and predictive medicine products | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen